Skip to main content

Table 5 Predictors of treatment failure in HIV-positive adults on MDR-TB treatment at Sizwe Tropical Disease Hospital, Johannesburg

From: Treatment outcomes in multidrug resistant tuberculosis-human immunodeficiency virus Co-infected patients on anti-retroviral therapy at Sizwe Tropical Disease Hospital Johannesburg, South Africa

 

aUnivariable Analysis

bMultivariable Analysis

Factor

IRR (95 % CI)

p-value

IRR (95 % CI)

p-value

ART regimen

    

 After

1.00

 

1.00

 

 Prior

1.01 (0.47–2.15)

0.988

0.80 (0.35–1.84)

0.606

Age groups

    

 18–45

1.00

   

 46–76

0.79 (0.27–2.28)

0.662

  

BMI

0.97 (0.87–1.07)

0.547

1.01 (0.94–1.09)

0.766

Haemoglobin (g/dl)

    

 Severe Anaemia (<7.0)

2.69 (0.78–9.30)

0.117

4.72 (1.47–15.08)

0.009*

 Moderate Anaemia (7.0–9.99)

1.09 (0.46–2.57)

0.839

0.97 (0.40–2.34)

0.944

 Mild Anaemia (10–10.99)

0.43 (0.10–1.87)

0.260

0.25 (0.03–1.82)

0.172

 Normal (≥11)

1.00

 

1.00

 

Infiltrative changes

    

 No

1.00

   

 Yes

1.01 (0.14–7.47)

0.990

  

Cavitary changes

    

 No

1.00

 

1.00

 

 Yes

1.81 (0.85–3.87)

0.125

2.14 (0.96–4.78)

0.064

Fibrotic changes

    

 No

1.00

   

 Yes

1.36 (0.41–4.50)

0.620

  

Comorbidity

    

 No

1.00

 

1.00

 

 Yes

1.79 (0.72–4.41)

0.207

2.39 (1.05–5.43)

0.039*

Adverse events

    

 No

1.00

 

1.00

 

 Yes

0.54 (0.24–1.23)

0.142

0.48 (0.21–1.09)

0.080

Regimen type at baseline

    

 Standardised

1.00

 

1.00

 

 Modified individualised

2.48 (1.18–5.20)

0.016*

2.15 (0.98–4.71)

0.056

  1. IRR Incidence rate ratio
  2. aUnadjusted models
  3. bAdjusted for Co-trimoxazole prophylaxis, BMI and categories of MDR-TB
  4. *Significant p <0.05